Company / Interest Expense
NeoGenomics Laboratories, Inc. Interest Expense History
FY2017-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$6.9M
FY2023
5-year range
$6.9M / $8.2M
FY2019-FY2023
Trend
-8.9%
vs FY2022
Sector context
#38 of 43
Health Care
What the data says
NeoGenomics Laboratories, Inc.'s interest expense of $7M is lower than 88% of companies in the Health Care sector (FY2023). Interest Expense has fluctuated over the past 7 years, ranging from $4M in FY2019 to $8M in FY2021.
Based on SEC 10-K filings.
$7M in FY2023 with a 5-year CAGR of +2.1%.
Improved from $8M to $7M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -0.5%
- 5-Year CAGR
- +2.1%
- 10-Year CAGR
- -
Sector benchmark
Top 12% in Health CareTop 12% of 43This company $6.9M Sector average $324.8M
▼
-97.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +2.1%, indicating consistent growth.
- In FY2023, interest expense decreased 8.9% year-over-year.
- Ranks #38 out of 43 companies in the Health Care sector.
- Peak interest expense was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $6.9M | -8.9% |
| FY2022 | $7.6M | -7.8% |
| FY2021 | $8.2M | +17.1% |
| FY2020 | $7.0M | +89.0% |
| FY2019 | $3.7M | -40.4% |
| FY2018 | $6.2M | +12.5% |
| FY2017 | $5.5M | - |
| FY2016 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026